AXIOS™ chaud pour le drainage des voies biliaires dans la sténose maligne (RAINBOW)
Étude prospective française sur le drainage des voies biliaires guidé par échographie endoscopique chez des patients atteints de sténose biliaire maligne (RAINBOW)
The study is designed to highlight the effectiveness of the Hot AXIOS™ stent when used in accordance with standard medical practice on the evolution of the quality of life of patients with malignant biliary stenosis requiring drainage of the bile ducts after failure of ERCP, in the two months after stent placement.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
The study will evaluate the quality of life in patients with malignant biliary obstruction after the placement of a lumen-apposing metal stent via endoscopic ultrasound, with an emphasis on the improvement of quality of life measured as a reduction in jaundice. Improvement in jaundice is a direct indicator of effective bile drainage and is expected to correlate with an enhancement in overall quality of life. Quality of life will be measured by means of subject response to the EORTC QLQ-BIL21, a component of the European Organization for Research and Treatment of Cancer (EORTC) designed specifically to assess the quality of life in patients with biliary tract cancer. The QLQ-BIL21 consists of 21 questions which aim to evaluate specific symptoms and issues relevant to patients with biliary tract cancer, such as jaundice, pain, digestive problems and the psychosocial impact of the disease.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Besançon, France, 25030
- CHU de Besançon
-
Cornebarrieu, France, 31700
- Clinique des Cedres, Ramsay Sante
-
Limoges, France, 87042
- CHU Limoges
-
Lyon, France, 69008
- Hopital Prive Jean Mermoz
-
Nantes, France, 44300
- Clinique Jules Verne
-
Nice, France, 06202
- CHU Nice
-
Paris, France, 75012
- Hopital Saint Antoine
-
Paris, France, 75908
- Hopital Europeen Georges-Pompidou
-
Paris, France, 75014
- Hopital Paris Saint-Joseph
-
Poitiers, France, 86021
- CHU de Poitiers
-
Reims, France, 51092
- CHU Reims
-
Rennes, France, 35033
- CHRU Hopital Pontchaillou
-
Rouen, France, 76000
- Clinique Saint-Hilaire
-
Saint-Herblain, France, 44800
- Santé Atlantique
-
Strasbourg, France, 67091
- CHU de Strasbourg
-
Toulouse, France, 31059
- CHU Rangueil
-
Vandœuvre-lès-Nancy, France, 54500
- CHRU de Nancy
-
Vichy, France, 03200
- Centre Hospitalier de Vichy
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients 18 years or older
- Willing and able to comply with study procedures and provide written informed consent
- Patients with failed ERCP for treatment of suspected malignant biliary obstruction
- Patients for whom an indication for Hot AXIOS™ stent placement has been determined
Exclusion Criteria:
- Women who are pregnant, nursing or planning to become pregnant during the study
- Patients with immediately resectable tumor or resectable during the two months of the study
- Patients for whom the placement of a double pigtail prosthesis is planned by the investigator during the index procedure
- Current participation in another investigation drug or device study that could interfere with the endpoints of this study
- Persons under guardianship or curatorship
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Hot AXIOS™ Recipients
The Hot AXIOS™ Stent is a flexible, fully covered self-expanding metal stent that is preloaded within the Electrocautery Enhanced Delivery System. Patients who meet all eligibility criteria will receive the Hot AXIOS™stent and their quality of life will be measured at baseline, two weeks after stent placement and two months after stent placement by the jaundice dimension of the EORTC QLQ-BIL21 questionnaire. A patient is considered enrolled after signing the study-specific Informed Consent Form (ICF). Patients who sign the ICF but subsequently do not meet one or more of the selection criteria will be considered screen failures and excluded from the study. |
The Hot AXIOS™ Stent and Electrocautery Enhanced Delivery System is commercially available and can be used to bridge two lumens or organs to create an internal drain, so as to drain the bile ducts in case of failure of ERCP.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of Life Measurement - Jaundice Dimension
Délai: 2 months (± 15 days)
|
The primary outcome is the difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the jaundice dimension consists of three of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Quality of Life Measurement - Non-Jaundice Dimension
Délai: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the non-jaundice dimension of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much); the non-jaundice dimension consists of 18 of those questions. A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Quality of Life Measurement - Global Score
Délai: 2 months (± 15 days)
|
The absolute difference between the measurement taken at 2 months of follow-up (± 15 days) and the baseline measurement of quality of life assessed by the global score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-BIL21). The QLQ-BIL21 consists of 21 questions to which respondents rate their experience with various symptoms or problems on a scale from 1 (Not at All) to 4 (Very Much). A lower score correlates to fewer symptoms or problems. |
2 months (± 15 days)
|
|
Reduction in Bilirubin (Clinical Success)
Délai: 2 weeks (+ 7 days) and 2 months (± 15 days)
|
Clinical success is defined as a reduction in bilirubin > 50% at each follow-up compared to baseline. |
2 weeks (+ 7 days) and 2 months (± 15 days)
|
|
Rate of Resolution of Clinical Symptoms
Délai: 2 months (± 15 days)
|
Resolution of GOO-related clinical symptoms such as jaundice, nausea/vomiting, fever/chills, weight loss and abdominal pain following implant of Hot AXIOS™ at 2 months of follow-up |
2 months (± 15 days)
|
|
Rate of Reintervention
Délai: 2 months (± 15 days)
|
Reintervention is defined as endoscopic, radiological or surgical intervention for the management of recurrent biliary obstruction due to stent dysfunction (e.g., obstruction or migration) at 2 months of follow-up. This criterion will be measured within the population for whom the placement of the Hot AXIOS™ stent was a technical success. |
2 months (± 15 days)
|
|
Chemotherapy Status
Délai: 2 months (± 15 days)
|
Number of days after study stent implantation to start or continuation of chemotherapy (if applicable). |
2 months (± 15 days)
|
|
Overall Survival
Délai: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the date of death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure overall survival. |
2 months (± 15 days)
|
|
Progression-Free Survival
Délai: 2 months (± 15 days)
|
Time from the placement of the Hot AXIOS™ to the earliest date of either disease progression or death from any cause or to the end of follow-up (end of study participation or lost to follow-up) to assess summary measure progression-free survival. |
2 months (± 15 days)
|
|
Number of Days Alive after Hospital Discharge
Délai: 2 months (± 15 days)
|
Number of days alive after hospital discharge within 2 months after the placement of the Hot AXIOS™. |
2 months (± 15 days)
|
|
Rate of Technical Success
Délai: 2 months (± 15 days)
|
Technical success is defined as the successful placement of the Hot AXIOS™ stent during study procedure. |
2 months (± 15 days)
|
|
Serious Adverse Events
Délai: 2 months (± 15 days)
|
Serious adverse events related to the study procedure and/or the Hot AXIOS™ stent. |
2 months (± 15 days)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Les enquêteurs
Les enquêteurs
- Chercheur principal: Jean-Baptiste Chevaux, Central Hospital, Nancy, France
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- E7209
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .